Sign up Australia
Proactive Investors - Run By Investors For Investors

MGC Pharmaceuticals rockets up 37% after reimbursement win for cannabis epilepsy therapeutic

The company has started manufacturing the product and plans to launch it later this year.
ASX gainer
MGC’s shares beat a declining broader market during trading today

MGC Pharmaceuticals Ltd (ASX:MXC) added 31.37% to its share price after its CannEpil medical cannabis product received an Australian Therapeutic Goods Administration approval to be prescribed for reimbursement to people with drug-resistant epilepsy.

The European company expects to make its reimbursable cannabis product available to the Australian market in December 2018 through pharmaceutical distributor HL Pharma.

A ‘validation’ of strategy

MGC Pharmaceuticals co-founder and managing director Roby Zomer said: “We are delighted to announce the availability of our first product CannEpil for supply under the Authorised Prescriber Scheme.

“This is a significant achievement for us and we are very excited at the prospect of ramping up production to a commercial scale and bringing CannEpil to Australia.

“This important step validates MXC’s seed-to-pharma strategy with the start of commercial revenues from our first investigational medicinal product offering.”

The company’s core business strategy is to develop and supply high-quality cannabinoid-based pharmaceutical products to medical markets in Europe, North America and Australasia.

MGC Pharmaceuticals tipped today it expects $1 million of annualised revenue from an initial base of 100 patients.

Earlier this year the company raised $5 million to build a fully-licensed medical cannabis facility in Malta to manufacture the clinically-tested therapeutic.

The company is one of a handful of companies to be awarded a full medical cannabis production and cultivation contract by the small European Union member.

A ‘milestone’ for people with epilepsy

Epilepsy Action Australia chief executive officer Carol Ireland welcomed the adding of CannEpil to Australia’s Authorised Prescriber Scheme.

Ireland said: “This is a significant milestone for epilepsy patients and other patient communities.

“It is another important step in improving access to potentially life-changing medications, and part of a global trend to recognise the valid medical benefits of cannabis.”

Ireland pointed to a global shift in focus towards patient rights and said today’s development was a “sign that patient needs and wants are (being) heard and respected.”

MGC Pharmaceuticals’ shares gained up to 1.6, or 31.37% today, to close at 6.7 cents. The company’s securities regularly changed hands for 7 cents during the trading day, frequently resting up 37.26%.

View full MXC profile View Profile

MGC Pharmaceuticals Ltd Timeline

Related Articles

1521490126_shutterstock_234586750.jpg
March 19 2018
The group has received key permits to allow cannabis - flowers and oils - to be imported into Australia from Aurora Cannabis Inc
scientist in lab
September 07 2018
Normally, patients have to wait until regulators have approved a drug before they get access to it, but up to 500 lupus sufferers will receive Lupuzor as part of a Managed Access Programme
Cyrptocurrencies
June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use